Equipoise abandoned? Randomization and clinical trials
Authors:
Open Access
- 1 October 2013
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 24 (10) , 2471-2474
Abstract
Randomized, clinical trials are the strongest method we have to define the efficacy of new drugs. Recently, however, novel agents that show remarkable responses with minimal toxicity in patients with advanced cancer have been discovered [1], and these present a challenge for the ethical conduct of randomized trials. Consequently, there is a debate on the randomized trial as the gold standard for bringing these agents to approval.Keywords
This publication has 16 references indexed in Scilit:
- Fool’s gold, lost treasures, and the randomized clinical trialBMC Cancer, 2013
- Equipoise and the Dilemma of Randomized Clinical TrialsNew England Journal of Medicine, 2011
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- Equipoise Lost: Ethics, Costs, and the Regulation of Cancer Clinical ResearchJournal of Clinical Oncology, 2010
- Ultimate Fate of Oncology Drugs Approved by the US Food and Drug Administration Without a Randomized TrialJournal of Clinical Oncology, 2009
- Cancer: The Road to AmiensJournal of Clinical Oncology, 2009
- Economics of New Oncology Drug DevelopmentJournal of Clinical Oncology, 2007
- Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysisThe Lancet Oncology, 2006
- For and against: Clinical equipoise and not the uncertainty principle is the moral underpinning of the randomised controlled trial FOR AGAINSTBMJ, 2000
- The Relation between Experience and Outcome in Heart TransplantationNew England Journal of Medicine, 1992